Background. Unique among high-income countries, Australia has used a 3 + 0 schedule (3 primary doses, no booster) for infant pneumococcal conjugate vaccine (PCV) since January 2005, initially 7 valent (PCV7) then 13 valent (PCV13) from July 2011. We measured vaccine effectiveness (VE) of both PCVs against invasive pneumococcal disease (IPD) using 2 methods.
Diseases caused by Streptococcus pneumoniae (pneumococcus) are a major cause of morbidity and mortality globally [1, 2] . In the developed world, serious pneumococcal disease occurs mainly in very young children and the elderly. Pneumococcal conjugate vaccines cover those serotypes that most frequently cause serious disease in normally sterile body sites, that is, invasive pneumococcal disease (IPD) [3] . The 7-valent pneumococcal conjugate vaccine (PCV7) became available in Australia in 2001 but was first publicly funded only for high-risk children. It was offered to all children starting in January 2005 through the National Immunisation Program (NIP) with a schedule of 3 doses at ages 2, 4, and 6 months (3 + 0 schedule). In 2011, PCV13 containing 6 additional serotypes (13v-non7v types), including 19A (the most common serotype to cause IPD following PCV7), replaced PCV7; the 3 + 0 schedule was continued for PCV13 [4] . For both PCVs, greater than 90% coverage was achieved rapidly.
Licensure of PCV13 was based on noninferiority to PCV7 using World Health Organization (WHO)-recommended criteria for an aggregate putative immune correlate of protection [5, 6] . However, when serotype-specific correlates of protection for PCV13 were estimated from comparison of post-licensure vaccine effectiveness (VE) measures to antibody levels achieved at age 5 months following doses at age 2 and 4 months, the thresholds exceeded the WHO-recommended 0.35 µg/mL level (used for PCV13 licensure) for several serotypes, most notably serotypes 3 and 19A [7] .
While in pivotal prelicensure trials of PCV7 and PCV13, the vaccine schedule consisted of 3 primary doses followed by a booster (3 + 1 schedule) [8, 9] ; the reduced dosage schedule adopted by the Australian NIP was expected to provide optimum protection in infancy when the incidence of meningitis is the highest. The WHO currently recommends a 3 + 0 schedule for PCVs based on 2 key systematic reviews [1, 10, 11] of data for PCV7. However, for PCV13, population-based impact assessments suggest that booster dose schedules (2 + 1 and 3 + 1) provide greater herd benefits, likely due to greater immune persistence beyond age 2 years when colonization levels for PCV13 types peak [12] [13] [14] [15] . A randomized, controlled trial comparing immunogenicity of PCV13 in 4 primary immunization schedules showed that a booster dose after priming with 3 doses at age 2, 4, and 6 months resulted in significantly increased antibody levels at around age 12 months for 7F, but not for 19A [16] . However, potential waning of antibody levels and vaccine-induced protection over time by vaccine schedule has not been evaluated.
VE studies help to bridge the evidence gap between clinical trial and immunogenicity data and routine use of PCVs for pneumococcal disease prevention [17] . For PCV7, post-licensure effectiveness estimates under a 3 + 1 schedule matched efficacy estimates from randomized, controlled trials [8, 18] . For both PCV7 and PCV13, effectiveness estimates against IPD are available for 3 + 1 and 2 + 1 schedules, but not for 3 + 0 schedule [7, [19] [20] [21] .
In this study, we assessed the effectiveness of PCV13 and PCV7 in Australian children against IPD using 2 study methods: matched case-control and indirect cohort [22] . We also examined change in VE with increasing time after completion of respective vaccine courses. Data used were from the national long-term enhanced IPD surveillance and vaccination register [23] [24] [25] .
METHODS

Selection of Cases and Controls
Cases
IPD cases for both study designs were sourced from the National Notifiable Disease Surveillance System (NNDSS), the population-based passive surveillance system for notifiable diseases in Australia. For surveillance, a case of IPD is defined as detection of S. pneumoniae from a normally sterile site, such as blood or cerebrospinal fluid, by culture or by nucleic acid amplification testing. Isolates from IPD cases are serotyped in 1 of 3 reference laboratories. Data flow, data elements, and data quality of NNDSS have been described elsewhere [26] .
For VE assessments, cases were those eligible to receive either PCV7 or PCV13 based on date of birth, aged ≥2 months at disease onset (eligible to receive at least 1 PCV dose), and disease onset before 31 When PCV13 was introduced, children who had incomplete PCV7 schedules were offered PCV13 for the remaining doses. For those up to age 3 years with a completed PCV7 course, a supplementary PCV13 dose was offered. Cases eligible for these mixed PCV schedules were excluded.
Controls for Matched Case-Control Design
Controls for this method were obtained from a de-identified dataset of the Australian Childhood Immunisation Register (ACIR), held by the National Centre for Immunization Research and Surveillance. The ACIR includes all children enrolled in the national publicly funded healthcare system (Medicare), which includes approximately 99% of children in Australia by age 12 months. Controls were matched to cases by date of birth (+/−4 days), indigenous status, and jurisdiction of residence. Since the method relies on discordance in vaccination status between cases and matched controls and given the high vaccine coverage for PCV (>90% for 3 doses at 12 months) and ready availability of controls from ACIR, 10 controls were sampled per case to maximize precision. The reference date for vaccination status assessment in controls was the IPD onset date in their matched case.
Controls for Indirect Cohort Design
In this method, cases due nonvaccine serotypes (NVTs) acted as controls on the assumption that the vaccine does not have any effect against these serotypes [22] . Cases due to vaccine-related serotypes with known cross-protection (6A for PCV7 and 6C for PCV13) were excluded from controls.
Vaccination Status Ascertainment
For eligible cases (and controls for the indirect cohort method), vaccination history was derived from NNDSS (usually in turn derived from ACIR); for controls in the matched case-control method, it was sourced directly from ACIR. Only doses of the respective PCV received >14 days prior to onset/reference date were counted. Children were considered unvaccinated if there was no record of any PCV doses or only 1 dose in the 14 days before the onset/reference date. Cases and controls with vaccination data missing were excluded.
Statistical Analyses
Analyses were performed using SPSS Statistics for Windows, version 22.0 (IBM Corp., Armonk, New York).
For the matched case-control design, odds ratios (ORs) of vaccination (vs no vaccination) in cases and controls and 95% confidence intervals (CIs) were generated using a conditional logistic regression (COXREG command in SPSS). For the indirect cohort method, similar ORs (and 95% CIs) adjusted for age were generated using binary logistic regression. Age adjustment was required for the indirect cohort method because of greater differences in age distribution among cases and controls within age strata feasible with available cases. VE was calculated as (1 -OR) × 100. VE was estimated using the number of doses and serotype/serotype category (vaccine-serotypes combined [VT], 13v-non7v types, VT-related serotypes, NVTs). For PCV7, cases and corresponding controls were limited to those aged ≤48 months to be comparable to PCV13 estimates. To investigate potential waning of VE, we first calculated ORs for 4 periods post-last dose (up to 12, 12-<24, 24-<36, and ≥ 36 months), with "not vaccinated" set as the reference category using the case-control method. Thereafter, we reset the reference category to "up to 12 months" post-last dose to generate relative odds of VT IPD for subsequent periods.
Modeling Potential Effect of Serotype Replacement on VE in Indirect Cohort Method
Differential changes in risk of NVT disease among the vaccinated group relative to the unvaccinated group could introduce bias in the indirect cohort method. We evaluated this bias by measuring the maximum difference between VE derived using the indirect cohort method (VE observed) and true VE for values of observed VE between 60% and 95% under an extreme scenario where increases in NVT incidence post-PCV introduction exclusively occurred in the vaccinated group, using the formula below [27] :
We used observed pre-and post-PCV7 and -PCV13 introduction NVT IPD incidence rates in children aged <5 years in Australia and 3-dose vaccine uptake estimates (at age 12 months) to calculate θ (Table 1) . 
RESULTS
There were 1209 and 308 IPD cases, respectively, in PCV7-eligible and PCV13-eligible children during the 10-year study period (2005) (2006) (2007) (2008) (2009) (2010) (2011) (2012) (2013) (2014) . Vaccination status was available for 1050 (86.8%) of PCV7-eligible and 300 (97.4%) of PCV13-eligible cases (Table 2 ). Few cases without available vaccination history were due to VTs (14/159 PCV7-eligible and 2/8 PCV13-eligible).
The mean age of PCV13-eligible cases (15.2 months; range, 2-40.2) was less than half that of PCV7-eligible cases (32.5 months; range, 2-107.0). The most common VT causing IPD in PCV7-eligible cases was 19F (n = 47, 4.5%), and 19A was the most common VT causing IPD in PCV13-eligible cases (n = 58, 19.3%). Receipt of 4 vaccine doses before disease onset was uncommon, with 93 among PCV7-eligible cases (86 [92%] NVTs) and 8 among PCV13-eligible cases (all NVTs). Total vaccine doses received by PCV-13 eligible cases were 670 compared with 912 over a similar period for PCV7-eligible cases, who were higher in number and older. Between years 1 and 4 post-vaccine introduction, annual 13-non7v serotype IPD cases increased 8.6-fold (from 5 to 43) in PCV13-eligible children vs a 2.4-fold (from 9 to 22) increase in VT IPD among PCV7-eligible children (Figure 1 ). The cumulative proportion who had received ≥1 dose of vaccine in all cases aged <12 months was less for PCV13-eligible (77.4%) than for PCV7-eligible (83.0%) but similar for all cases aged <18 months (Figure 2 ).
For the case-control method, we matched 10 501 controls from ACIR to PCV7-eligible cases and 3003 to PCV13-eligible cases. For the indirect cohort method, NVT cases available as controls were 850 for PCV7 and 167 for PCV13.
For VE of ≥1 dose of PCV7 against VT IPD in children aged ≥2 to 48 months, case-control and indirect cohort methods gave almost identical estimates (72% and 73%, Table 3 ). Among infants aged 2 to <12 months, VE for ≥1 dose of PCV7 by the case-control method was 80.0% (95% CI, 50.2% to 92.0%). For PCV13, VE of ≥1 dose against VT IPD in children aged ≥2 months to a maximum of 42 months was 71.3% (95% CI, 48.3% to 84.0%) using the case-control method and 75.6% (95% CI, 46.4% to 88.9%) using the indirect cohort method. When limited to the infant age group of 2 to <12 months, VE estimates for 3 doses of PCV13 were 86.5% (95% CI, 11.7% to 97.9%) by case-control method and 94.4% (95% CI, 71.1% to 98.9%) by indirect cohort method.
Vaccine Effectiveness by Time Since Last Dose
For PCV7, declines in 3-dose VE estimates for VT IPD were seen in successive 12-month periods, from 89.4% (95% CI, 75.8% to 95.3%) in the first 12 months post-dose 3 to 74.0% (95% CI, 23.9% to 91.1%) between 12 and 24 months and 40.7% (95% CI, <-100.0% to 84.7%) between 24 and 36 months. Similarly, VE for 3 PCV13 doses decreased from 87.1% (95% CI, 
Effect of Serotype Replacement on Vaccine Effectiveness in Indirect Cohort Method
Our modeling of the impact of serotype replacement on indirect cohort method estimates found that with high vaccine uptake, when VE estimates using the indirect cohort method were high (≥90%), they approximated true VE (Supplementary Appendix Figure 1a ). This was true even in the extreme scenario, where all NVT increases were assumed to occur in vaccinated children. However, when VE estimates from the indirect cohort were low and NVT increases were high (such as in the mature PCV7 period), we estimated that the indirect cohort method could inflate VE by up to about 40%.
DISCUSSION
In this study, we are the first to explore the effectiveness of PCVs against IPD using a 3 + 0 schedule. Our findings complement impact assessments for both PCV7 and PCV13 in this schedule, unique to Australia among high-income countries, in the context of rapidly attained high vaccine uptake [14, 28, 29] . Notably, both PCVs had high effectiveness in infancy when incidence of pneumococcal meningitis, the most severe form of IPD, is highest. For both vaccines, VE point estimates showed a progressive decrease with increasing time since the third dose, with a significant increase in relative likelihood of VT IPD beyond 24 months compared to the first 12 months after dose 3. As the case-control method did not show significantly increased risk of NVT disease in those vaccinated, any substantial overestimation of VE by the indirect cohort method is unlikely, as observed previously for PCV7 [27] .
Ours is the only study to explore VE waning for PCV13, finding declines in VE between 12 and 24 months after a 3-dose schedule completion of 17%, with further reductions of about 46% in the next 12 months. For PCV7, a waning pattern similar to ours for 3 doses, but more stable VE for 4 doses, was found in Invasive pneumococcal disease cases in children eligible to receive pneumococcal conjugate vaccine 7 (PCV7) (n = 1050) and PCV13 (n = 300) in respective vaccination programs by age at disease diagnosis and cumulative proportions that had received at least 1 respective vaccine dose. Abbreviations: PCV7, 7-valent pneumococcal conjugate vaccine; PCV13, 13-valent pneumococcal conjugate vaccine.
the United States [27] . It is plausible that doses given only prior to age 12 months yield a shorter duration of protection due to poorer B-cell response compared to doses given in the second year of life, as documented in the PCV7 trial among Navajo and White Mountain Apache Indian children [30] .
For PCV7, VE estimates across 3 + 0, 2 + 1, and 3 + 1 schedules in different settings were similar, consistent with impact assessments [31] . For PCV13, VE estimates against 13v-non-7v types were similar between the United Kingdom's 2 + 1 schedule and our 3 + 0 schedule [7] but 10%-15% higher for the 3 + 1 schedule in studies from the United States and Germany [20, 32] (Table 5 ). This comparison also suggests a lower VE against serotype 3 with 3-dose schedules, which is consistent with immunogenicity data [7] . The point estimate for VE against all PCV7 types combined was greater for PCV7 than for PCV13 in our study and in other studies [7, 21, 33] . Lower immunogenicity of PCV13 for common serotypes after infant series that persisted to some extent even after the toddler dose was seen in prelicensure trials [9, 34] . Post-dose 3 antibody responses for PCV13 did not reach prespecified noninferiority criteria compared to PCV7 for 6B and 9V [9] . These data suggest that this lower protective effect against IPD due to the common serotypes of PCV13 than PCV7 is likely due to inherent properties of the 2 vaccines.
Of equal, and arguably greater, importance than PCVinduced direct protection is the magnitude of indirect impact on unimmunized cohorts. For PCV7, 19F IPD incidence declined to levels similar to other VTs with continued high coverage, despite lower VE, which is consistent with eradication of carriage over time [28, 35, 36] . In contrast, 19A remains the most common serotype to cause breakthrough IPD among Australian children, even after 4 years of high PCV13 coverage and despite being the serotype that PCV13 has the highest VE against.
A limitation in our matched case-control design is potential misclassification bias, as we were unable to definitively exclude possible cases among ACIR-derived controls; however, given the low population incidence of IPD, such misclassification is highly unlikely. We were unable to control for potential confounders, such as household crowding and comorbidities associated with increased risk of IPD, as these data are not captured by ACIR. In studies that used the traditional case-control method in the United States and the indirect cohort method in the United Kingdom, effectiveness of PCV13 and PCV7, respectively, did not differ significantly with the presence of such risk factors [20, 33] . However, it is possible that our VE estimates could differ if we were able to control for these risk factors. In the Australian program, children with at-risk medical conditions, including those that cause immunosuppression, and all indigenous children resident in 4 high-incidence jurisdictions are offered a fourth PCV dose. Among cases in our study who had received 4 doses, none of the PCV13-eligible and only 8% of PCV7-eligible had VT disease. Thus, our estimates of VE against VT IPD apply almost exclusively to the 3 + 0 schedule. Variability in age distribution in VT and NVT IPD may affect VE estimation in the indirect cohort method, and it is the likely reason for any discrepancy between VE estimates in some age strata between the 2 methods. Possible interaction of influenza with IPD has been described, with suggestion that influenza virus downregulates innate immune responses to pneumococcus [37] . However, comparison of notifications to NNDSS of influenza and IPD in concurrent periods did not show a strong association [14, 38] . In future studies where there are sufficient IPD case numbers, it would be useful to examine variation in VE of PCV with influenza activity.
In summary, our study, the first to measure the effectiveness of PCV7 and PCV13 in a 3 + 0 schedule and to use 2 methods of estimation, shows high effectiveness in infancy and suggestive waning over time, particularly beyond 24 months of course completion. On 1 September 2017, the Australian National Immunisation Technical Advisory Group recommended a change in the PCV13 schedule from 3 + 0 to 2 + 1 for children. This was in response to increasing PCV13 breakthrough cases and lesser indirect reductions in VT IPD in older age groups [39] , possibly due to persistent colonization with vaccine serotypes [40] . A precise comparison of VE between PCV schedules, particularly for serotype-specific estimates more relevant in other settings, would require expanded sample sizes only achievable by metaanalytic methods [31] .
Supplementary Data
Supplementary materials are available at Clinical Infectious Diseases online. Consisting of data provided by the authors to benefit the reader, the posted materials are not copyedited and are the sole responsibility of the authors, so questions or comments should be addressed to the corresponding author.
Notes assistance with access to Australian Childhood Immunisation Register to source controls for the case-control method and Catherine King, information manager at NCIRS, for her assistance in literature searches. We also acknowledge the Enhanced invasive pneumococcal disease (IPD) Surveillance Working Group of the Communicable Diseases Network Australia and all public health officers involved in the collection of surveillance data; state and territory public health communicable disease and surveillance units; and all laboratories that support national IPD surveillance in Australia.
Disclaimer. The views expressed in this article are not necessarily those of the Australian Government Department of Health. The Department of Health had no role in study design, data analysis, data interpretation, or writing of the report. Financial support. This study was conducted at the NCIRS, which receives funding from the Australian Government Department of Health.
Potential conflicts of interest. 
